Abnormal fusion transcript linked to prostate cancer

Share this article:
Abnormal Fusion Transcript Linked to Prostate Cancer
Abnormal Fusion Transcript Linked to Prostate Cancer

(HealthDay News) -- A fusion transcript generated in prostate cancers without chromosomal rearrangement is associated with prostate cancer growth and disease progression, according to a study published online June 19 in Cancer Discovery.

Yanmei Zhang, Ph.D., from the University of Virginia in Charlottesville, and colleagues examined the expression of the chimeric SLC45A3-ELK4 fusion transcript, in the absence of chromosomal rearrangement, in prostate cancer cell lines and primary tumors.

The researchers found that the SLC45A3-ELK4 fusion transcript was produced through cis-splicing of adjacent genes (cis-SAGe) and read through, with no evidence of chromosomal rearrangement. There was an inverse correlation seen between the binding of CCCTC-binding factor to the insulator sequences and expression of the chimera transcript. The fusion transcript promoted the growth of prostate cancer in culture, and levels correlated with disease progression, with the highest levels in prostate cancer metastases.

"In conclusion, our results suggest that cis-SAGe could be an alternative pathway to generate gene fusions in the absence of DNA rearrangement," Zhang and colleagues write. "Given that most chimeric gene fusions play causal roles in tumorigenesis, it is conceivable that abnormal cis-SAGe might be a novel epigenetic way to drive cancer."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Interval tumors found in six percent of colorectal cancer cases

Interval tumors found in six percent of colorectal ...

Interval cancers more likely to be earlier stage, proximal, have lower risk of death

Reliance on Windows XP may threaten data security

Reliance on Windows XP may threaten data security

Continued security of patient data is needed following Microsoft's termination of XP support.

Perioperative chemotherapy increases bladder cancer survival

Perioperative chemotherapy increases bladder cancer survival

Study shows low utilization of bladder cancer perioperative chemotherapy is associated with a survival benefit in the general population.